Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:20 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053549
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total revenues | 238,946 | 1,214 | 238,917 | 4,246 |
| Operating expenses: | ||||
| Cost of revenue | — | 11 | — | 11 |
| Research and development | 135,283 | 97,509 | 244,205 | 216,154 |
| Selling, general and administrative | 30,196 | 22,283 | 53,535 | 46,227 |
| Restructuring, long-lived assets impairment and related charges, net | — | (172) | — | (182) |
| Total operating expenses | 165,479 | 119,631 | 297,740 | 262,210 |
| Income (loss) from operations | 73,467 | (118,417) | (58,823) | (257,964) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Vir Biotechnology, Inc.'s R&D?
- Vir Biotechnology, Inc. (VIR) reported R&D of $135.28M in Q2 2026.
- How has Vir Biotechnology, Inc.'s R&D changed year-over-year?
- Vir Biotechnology, Inc.'s R&D increased by 38.7% year-over-year, from $97.51M to $135.28M.
- What is the long-term trend for Vir Biotechnology, Inc.'s R&D?
- Over 4 years (2021 to 2025), Vir Biotechnology, Inc.'s R&D has grown at a 0.4% compound annual growth rate (CAGR), from $448.01M to $455.97M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Vir Biotechnology, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude